Biogen Exploring Tecfidera Safety Perceptions As Sales Slowdown Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Slowing sales growth continues for Biogen’s Tecfidera in the first quarter, due in part to lingering questions regarding safety. In an April 24 earnings call, the company also provided an update on Phase III study plans for its Alzheimer’s candidate, aducanumab.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.
Payer Transparency Reforms: Moving From Rebates To Drug Access Restrictions
Institute for Clinical and Economic Review analysis of whether payers are providing ‘fair access’ to fairly priced drugs was hampered by a lack of transparency among payers, leading to calls for reform.